Johnson & Johnson $JNJ Shares Bought by SCS Capital Management LLC

SCS Capital Management LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 207.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 171,664 shares of the company’s stock after acquiring an additional 115,759 shares during the quarter. SCS Capital Management LLC’s holdings in Johnson & Johnson were worth $26,222,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $35,000. Stone House Investment Management LLC acquired a new position in Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson in the first quarter worth about $48,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Johnson & Johnson by 66.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after acquiring an additional 150 shares during the last quarter. Finally, Pandora Wealth Inc. bought a new position in shares of Johnson & Johnson during the 1st quarter valued at about $65,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 1.5%

NYSE:JNJ opened at $202.24 on Friday. The business’s fifty day moving average price is $193.61 and its 200 day moving average price is $174.90. The firm has a market capitalization of $487.25 billion, a price-to-earnings ratio of 19.52, a PEG ratio of 2.29 and a beta of 0.36. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $207.81.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.6%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Wall Street Analyst Weigh In

Several analysts recently commented on JNJ shares. Morgan Stanley set a $190.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Citigroup raised their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $202.10.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.